Literature DB >> 1973055

The existence of an inactive form of transglutaminase within metastasising tumours.

C R Knight1, R C Rees, B M Elliott, M Griffin.   

Abstract

Separation by anion exchange chromatography of detergent extracts from a poorly metastatic HSV-2-induced hamster fibrosarcoma, its highly metastatic variant and a highly metastatic rat fibrosarcoma indicated the presence of an inactive form of transglutaminase antigen, when eluent fractions were assayed for transglutaminase activity and antigen. This inactive antigenic transglutaminase was clearly separable from the particulate and cytosolic forms of the transglutaminase enzyme. Unlike tumours, its presence could not be demonstrated in extracts from normal rat liver. Measurement of activity levels during tumour growth indicated that the progression of the two highly metastatic tumours was accompanied by a decrease in cytosolic transglutaminase activity, whilst the activity of this enzyme form remained constant in the poorly metastatic tumour. Measurement of antigen levels indicated an inverse relationship between the level of inactive transglutaminase and the level of cytosolic transglutaminase activity, suggesting that the two forms are inter-related. Gel filtration indicated the molecular weight of the inactive form to be greater than both the particulate and cytosolic forms, and it was estimated to be 120,000. Partial proteolysis of the semi-purified inactive form, by either trypsin or thrombin, led to its activation and to the appearance of a transglutaminase similar in molecular weight and ionic mobility, both by anion-exchange chromatography and electrophoresis, to the cytosolic transglutaminase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973055     DOI: 10.1016/0167-4889(90)90019-a

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Authors:  Lei Xu; Shahinoor Begum; Jeremy D Hearn; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  Enhanced apoptosis in transformed human lung fibroblasts after exposure to sodium butyrate.

Authors:  G L Thomas; A Henley; T C Rowland; A Sahai; M Griffin; P J Birckbichler
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-09       Impact factor: 2.416

3.  The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis.

Authors:  T S Johnson; M Griffin; G L Thomas; J Skill; A Cox; B Yang; B Nicholas; P J Birckbichler; C Muchaneta-Kubara; A Meguid El Nahas
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Induction of tissue transglutaminase by dexamethasone: its correlation to receptor number and transglutaminase-mediated cell death in a series of malignant hamster fibrosarcomas.

Authors:  T S Johnson; C I Scholfield; J Parry; M Griffin
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Characterisation of a human glioblastoma cell line (LI) expressing hypothalamic and pituitary hormones.

Authors:  A Savarese; M Annicchiarico-Petruzzelli; G Citro; G Zupi; L G Spagnoli; A Colantoni; P Vernole; A Stephanou; R A Knight; P Guerrieri
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

6.  Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukaemia and solid tumour target cells.

Authors:  C R Knight; R C Rees; A Platts; T Johnson; M Griffin
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

7.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

Authors:  H J Dubbink; N S Verkaik; P W Faber; J Trapman; F H Schröder; J C Romijn
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

Review 8.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

9.  Upregulation of transglutaminase and ε (γ-glutamyl)-lysine in the Fisher-Lewis rat model of chronic allograft nephropathy.

Authors:  Badri Shrestha; Imran Butt; Michelle Da Silva; Armando Sanchez-Lara; Bart Wagner; Andrew Raftery; Timothy Johnson; John Haylor
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.